CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1543-1549

  Sørensen, Rikke Bæk ^a   Andersen, Rikke Sick ^a   Svane, Inge Marie ^a,b   Engeii Noerregaard, Lotte ^a,b   Hadrup, Sine R ^d   Baisiev, Eva ^c   Andersen, Mads Haid ^a   Straten, Per Thor ^a,c  

^a Center for Cancer Immune Therapy   (Denmark)

^b Department of Oncoiogy ^*  (Denmark)

^c University Hospitai Heriev   (Denmark)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLLEUCYLTYROSYLLEUCYLMETHIONYLGLUTAMYLLEUCYLTHREONYLMETHIONINE; ALANYLLYSYLTYROSYLLEUCYLMETHIONYLGLUTAMYLLEUCYLCYSTEINYLCYSTEINE; ALANYLLYSYLTYROSYLLEUCYLMETHIONYLGLUTAMYLLEUCYLTHREONYLMETHIONINE; ALANYLMETHIONYLTYROSYLLEUCYLMETHIONYLGLUTAMYLTHREONYLMETHIONINE; CYCLIN B1; HLA A2 ANTIGEN; PEPTIDE; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL; CANCER PATIENT; CD8+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CYCLIN B; FEMALE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA; MIDDLE AGED; MUTATION; PEPTIDE FRAGMENTS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63449085836     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1412     Document Type: Article

References (34)

1. Novellino L, Castelli C, Parmiani G. Alisting of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54:187-207.
2. Parmiani G, Pilla L, Castelli C, Rivoltini L. Vaccination of patients with solid tumours. Ann Oncol 2003;14: 817-24.
3. Silk AW, Finn OJ. Cancer vaccines: a promising cancer therapy against all odds. Future Oncol 2007;3: 299-306.
4. Brinkman JA, Fausch SC, Weber JS, Kast WM. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 2004;4:181 -98.
5. Meier A, Reker S, Svane IM, et al. Spontaneous CTL responses against peptides derived from the taxol resistance associated gene-3 (Trag-3) protein in cancer patients. Cancer Immunol Immunother 2005;54: 219 -28.
6. Andersen MH, Becker JC, thor Straten P. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005;4:399 -409.
7. Kao H, Marto JA, Hoffmann TK, et al. Identification of cyclin B1 as a shared human epithelial tumor-associat-edantigen recognized byTcells. J Exp Med 2001;194:1313-23.
8. Ropke M, Hald J, Guldberg P, et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A1996;14704-14707.
9. Suzuki T, Urano T, Miki Y, et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci 2007;98:644-51.
10. Singhal S, Vachani A, Ntin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis,andangiogenesisbiomarkersinnon-smallcell lung cancer: a review. Clin Cancer Res 2005;11: 3974-86.
11. Yu M, Zhan Q, Finn OJ. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 2002;38:981 -7.
12. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002;1: 289-98.
13. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat1997;9: 348-55.
14. Kao H, Amoscato AA, Ciborowski P, Finn OJ. A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells. Clin Cancer Res 2001;7:773 -80s.
15. Svane IM, Pedersen AE, Johansen JS, et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007;56:1485-99.
16. Andersen MH,Svane IM, Kvistborg P, et al. Immunogenicity of Bcl-2 in cancer patients. Blood 2005; 105:728 -34.
17. McCutcheon M, Wehner N, Wensky A, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997; 210:149-66.
18. Andersen MH, Ostergaard Pedersen L, Becker JC, thor Straten P. Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients. Cancer Res2001;61:869-72.
19. 19. Toebes M, Coccoris M, Bins A, et al. Design and use of conditional MHC class I ligands. Nat Med 2006;12: 246-51.
20. Rodenko B, Toebes M, Hadrup SR, et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 2006;1: 1120-32.
21. Hanahan D,Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
22. Andersen MH, Sorensen BS, Schrama D, Svane IM, Becker JC, thor Straten P. Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother. E-pub ahead of print 2008.
23. Wölfel T, Hauer M, Schneider J, et al. A p16INK4a- insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science1995;269: 1281 -4.
24. Egloff AM,Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006; 66:6-9.
25. Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001; 61:6459-66.
26. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008;105: 3849-54.
27. Derre L, Ferber M, Touvrey C, et al. A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J Immunol 2007;179:7635-45.
28. Pittet MJ, Zippelius A, Speiser DE, et al. In vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach forTcell monitoring in infectious and malignant diseases. J Immunol 2001;166:7634-40.
29. Speiser DE, Lienard D, Pittet MJ, et al. In vivo activation of melanoma-specific CD8(+) Tcells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002;32:731 -41.
30. Petersen TR,Buus S,BrunakS, Nissen MH, Sherman LA, Claesson MH. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 2001;53:357-64.
31. Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
32. Andersen MH, Fensterle J, Ugurel S, et al. Immunogenicity of constitutively active V599EBRaf. Cancer Res2004;64:5456-60.
33. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 2007; 19:203-8.
34. Yamshchikov GV, Mullins DW, Chang CC, et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 2005;174:6863-71.